IBRX — ImmunityBio, Inc.

Is IBRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of July 5, 2026

ImmunityBio, Inc. (IBRX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Biotechnology) last closed at $9.44. The rating moved from Overbought to Neutral on July 2, 2026 and has changed 27 times in the last 90 days.

Public ratingNeutral (as of July 5, 2026)
Last close$9.44
Rating changesRating changed 27 times in the last 90 days
Last changeMoved from Overbought to Neutral on July 2, 2026
SectorHealthcare
IndustryBiotechnology

Latest MarketMoodz coverage

Cramer Backs CAVA in Mad Money Lightning Round2026-06-16
ImmunityBio Gains FDA Acceptance for Expanded ANKTIVA Use2026-05-20
FDA Flags Anktiva Claims as ImmunityBio Pushes Regulatory Fixes2026-04-06
NCCN Expands Anktiva Guideline for Papillary NMIBC; ImmunityBio Stock Rises2026-03-17
ImmunityBio Resubmits ANKTIVA for Expanded NMIBC Use2026-03-09

See today's live rating, score and targets

Members see the live hourly rating for IBRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.